Treatments with huge promise don't always pan out the way you'd expect.
News & Analysis: VIVUS
Vivus Inc shares tanked today following results that failed to impress.
Instead of Ebola drugmakers, investors may be better served focusing on these healthcare trends.
The CDC is doing its best to curb this disease, but a recent Gallup survey suggests that more people have this disease than ever before!
Instead of shrinking waistlines, VIVUS shareholders saw their shares shrink in value by 14% in December. Find out what troubled VIVUS in December and whether or not this dip represents a buying opportunity.
I’d prefer coal in my stocking to these three troubled biotech stocks.
Aegerion Pharmaceuticals, MannKind Corp., and VIVUS, Inc. have all attracted short sellers in droves this year. With each company facing serious headwinds, should investors avoid these struggling biotechs?
A recent World Health Organization study shows that this growing problem is responsible for nearly a half-million cancer diagnoses each year.
Europe is key for Orexigen's Contrave. Shares jumped despite problems with the U.S. launch.
Here are three stocks that have gotten crushed lately. Are any of them worth buying?